The power of probiotics for immune health

The gut-immune axis is the bidirectional relationship between the gut microbiome and the body’s immune system. Because the gut hosts an estimated 70–80% of the body’s immune cells, the composition and diversity of the gut microbiota directly influences how effectively the immune system distinguishes between harmful pathogens and harmless microorganisms.

For brands developing immune health products, this mechanism is commercially significant. It explains why a probiotic ingredient can legitimately anchor an immune health positioning strategy by supporting microbiota diversity, gut barrier integrity, and microbial balance. It also means the claims’ opportunity in this category isn’t limited to general “immune support.” Strain-specific probiotics can target defined pathways within this axis, from mucosal support to systemic immune response regulation, enabling more substantiated and differentiated product positioning.

Probiotic strains with clinical evidence for immune health include Lactobacillus plantarum DR7® and the dual-strain combination of L. plantarum KABP® 031 and KABP® 032, found in KABP® Innerim — both backed by human clinical research and mechanism-specific data. Kaneka Probiotics also offers KABP® AB21®, a four-strain blend with research in children’s immunity.

L. plantarum DR7® is supported by three clinical studies demonstrating immune response support and upper respiratory tract health benefits, including increases in immune enhancement biomarkers. KABP® Innerim, formulated specifically for immune modulation in mature adults, is backed by six clinical studies and in vitro research showing stimulation of IL-10, an essential immunoregulator in the GI tract.

Probiotics support upper respiratory tract (URT) health through the gut-immune axis, which is the communication network between the gut microbiome and the body’s broader immune defenses. Because the gut is the primary site where the immune system encounters and responds to external microorganisms, specific probiotic strains can prime immune cells that patrol not just the GI tract, but respiratory mucosal surfaces as well.

Lactobacillus plantarum DR7® is clinically studied for URT health support and immune response, with evidence demonstrating increases in immune enhancement biomarkers relevant to respiratory defense.

Immune stimulation refers to broadly activating the immune response, increasing immune cell activity or output. Immune modulation refers to promoting the regulation and balance of the immune system, supporting a calibrated response rather than simply amplifying immune activity.

For probiotic formulators, immune stimulation positioning may be appropriate for short-term, acute immune support contexts. Immune modulation is often a more precise and defensible claim, particularly for products targeting mature adults, whose immune systems tend to benefit more from balanced regulation than from broad activation. KABP® Innerim is specifically formulated and clinically studied for immune modulation in mature adults, with in vitro research demonstrating stimulation of IL-10, a cytokine that functions as an essential immunoregulator in the GI tract.

Clinical biomarkers used to evaluate probiotic immune efficacy include cytokine profiles (such as IL-10, a key immunoregulator), secretory IgA levels (a marker of mucosal immunity), NK cell activity, and immune enhancement biomarkers that reflect measurable changes in innate and adaptive immune function.

For brands evaluating probiotic ingredients for immune health positioning, biomarker data is one of the most important differentiators to assess in a supplier’s evidence package. Ingredient partners should be able to demonstrate that their strains have moved clinically relevant immune markers in human trials — not just in vitro or animal models alone. L. plantarum DR7® has clinical data demonstrating increases in immune enhancement biomarkers. KABP® Innerim has in vitro evidence for IL-10 stimulation.